



COPY OF PAPERS  
ORIGINALLY FILED

#11  
PATENT  
6/4/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ariel Fletcher  
Ariel Fletcher

4/30/2002  
Date of Deposit

Applicant: Madison

Serial No.: 09/600,985

Filed: November 13, 2000

Title: TISSUE TYPE PLASMINOGEN  
ACTIVATOR (t-PA) VARIANTS:  
COMPOSITIONS AND METHODS  
OF USE

)  
) Group Art Unit: 1653  
)  
) Examiner: H. Schnizer  
)  
)  
) Our Ref.: TSRI 568.1  
)  
)  
)  
)

RECEIVED  
MAY 16 2002  
TECH CENTER 1600/2900

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the enclosed copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed March 14, 2002, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Sequence Listing is labeled TSRI 568.1.

Applicants respectfully request entry of the Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance

B

with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

If there are any fees associated with this request, please charge our Deposit Account 19-0962.

April 30, 2002  
Date

Michael J. McCarthy  
Michael J. McCarthy, Reg No. 46,910

THE SCRIPPS RESEARCH INSTITUTE  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, California 92037  
(858) 784-2937



## SEQUENCE LISTING

B1 <110> Madison, Edwin L

<120> TISSUE TYPE PLASMINOGEN ACTIVATOR (t-PA)  
VARIANTS HAVING ZYMOGEN CHARACTERISTICS: COMPOSITIONS AND  
METHODS OF USE

<130> TSRI 568.1

<140> US 09/600,985

<141> 2000-11-13

<150> PCT/WO98/21320

<151> 1996-11-12

<160> 10

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 527

<212> PRT

<213> Homo sapiens

<400> 1

R 0320

Ser	Tyr	Gln	Val	Ile	Cys	Arg	Asp	Glu	Lys	Thr	Gln	Met	Ile	Tyr	Gln
1				5					10					15	
Gln	His	Gln	Ser	Trp	Leu	Arg	Pro	Val	Leu	Arg	Ser	Asn	Arg	Val	Glu
			20					25					30		
Tyr	Cys	Trp	Cys	Asn	Ser	Gly	Arg	Ala	Gln	Cys	His	Ser	Val	Pro	Val
			35				40					45			
Lys	Ser	Cys	Ser	Glu	Pro	Arg	Cys	Phe	Asn	Gly	Gly	Thr	Cys	Gln	Gln
	50					55				60					
Ala	Leu	Tyr	Phe	Ser	Asp	Phe	Val	Cys	Gln	Cys	Pro	Glu	Gly	Phe	Ala
65					70				75					80	
Gly	Lys	Cys	Cys	Glu	Ile	Asp	Thr	Arg	Ala	Thr	Cys	Tyr	Glu	Asp	Gln
				85				90						95	
Gly	Ile	Ser	Tyr	Arg	Gly	Thr	Trp	Ser	Thr	Ala	Glu	Ser	Gly	Ala	Glu
			100					105					110		
Cys	Thr	Asn	Trp	Asn	Ser	Ser	Ala	Leu	Ala	Gln	Lys	Pro	Tyr	Ser	Gly
		115					120					125			
Arg	Arg	Pro	Asp	Ala	Ile	Arg	Leu	Gly	Leu	Gly	Asn	His	Asn	Tyr	Cys
	130					135					140				
Arg	Asn	Pro	Asp	Arg	Asp	Ser	Lys	Pro	Trp	Cys	Tyr	Val	Phe	Lys	Ala
145					150					155				160	
Gly	Lys	Tyr	Ser	Ser	Glu	Phe	Cys	Ser	Thr	Pro	Ala	Cys	Ser	Glu	Gly
				165				170						175	
Asn	Ser	Asp	Cys	Tyr	Phe	Gly	Asn	Gly	Ser	Ala	Tyr	Arg	Gly	Thr	His
			180				185						190		
Ser	Leu	Thr	Glu	Ser	Gly	Ala	Ser	Cys	Leu	Pro	Trp	Asn	Ser	Met	Ile
		195					200					205			
Leu	Ile	Gly	Lys	Val	Tyr	Thr	Ala	Gln	Asn	Pro	Ser	Ala	Gln	Ala	Leu
	210					215				220					
Gly	Leu	Gly	Lys	His	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Asp	Ala	Lys
225					230					235				240	

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900

Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys  
 245 250 255  
 Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro  
 260 265 270  
 Gln Phe Glu Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro  
 275 280 285  
 Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu Arg  
 290 295 300  
 Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala  
 305 310 315 320  
 Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile  
 325 330 335  
 Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe  
 340 345 350  
 Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Asp Thr Tyr  
 355 360 365  
 Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys  
 370 375 380  
 Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp  
 385 390 395 400  
 Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys  
 405 410 415  
 Asp Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His  
 420 425 430  
 Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn  
 435 440 445  
 Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly  
 450 455 460  
 Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly  
 465 470 475 480  
 Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile  
 485 490 495  
 Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr  
 500 505 510  
 Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro  
 515 520 525

<210> 2  
 <211> 527  
 <212> PRT  
 <213> Homo sapiens

<400> 2  
 Ser Tyr Gln Val Ile Cys Arg Asp Glu Lys Thr Gln Met Ile Tyr Gln  
 1 5 10 15  
 Gln His Gln Ser Trp Leu Arg Pro Val Leu Arg Ser Asn Arg Val Glu  
 20 25 30  
 Tyr Cys Trp Cys Asn Ser Gly Arg Ala Gln Cys His Ser Val Pro Val  
 35 40 45  
 Lys Ser Cys Ser Glu Pro Arg Cys Phe Asn Gly Gly Thr Cys Gln Gln  
 50 55 60  
 Ala Leu Tyr Phe Ser Asp Phe Val Cys Gln Cys Pro Glu Gly Phe Ala  
 65 70 75 80  
 Gly Lys Cys Cys Glu Ile Asp Thr Arg Ala Thr Cys Tyr Glu Asp Gln  
 85 90 95  
 Gly Ile Ser Tyr Arg Gly Thr Trp Ser Thr Ala Glu Ser Gly Ala Glu

100 105 110  
 Cys Thr Asn Trp Asn Ser Ser Ala Leu Ala Gln Lys Pro Tyr Ser Gly  
 115 120 125  
 Arg Arg Pro Asp Ala Ile Arg Leu Gly Leu Gly Asn His Asn Tyr Cys  
 130 135 140  
 Arg Asn Pro Asp Arg Asp Ser Lys Pro Trp Cys Tyr Val Phe Lys Ala  
 145 150 155 160  
 Gly Lys Tyr Ser Ser Glu Phe Cys Ser Thr Pro Ala Cys Ser Glu Gly  
 165 170 175  
 Asn Ser Asp Cys Tyr Phe Gly Asn Gly Ser Ala Tyr Arg Gly Thr His  
 180 185 190  
 Ser Leu Thr Glu Ser Gly Ala Ser Cys Leu Pro Trp Asn Ser Met Ile  
 195 200 205  
 Leu Ile Gly Lys Val Tyr Thr Ala Gln Asn Pro Ser Ala Gln Ala Leu  
 210 215 220  
 Gly Leu Gly Lys His Asn Tyr Cys Arg Asn Pro Asp Gly Asp Ala Lys  
 225 230 235 240  
 Pro Trp Cys His Val Leu Lys Asn Arg Arg Leu Thr Trp Glu Tyr Cys  
 245 250 255  
 Asp Val Pro Ser Cys Ser Thr Cys Gly Leu Arg Gln Tyr Ser Gln Pro  
 260 265 270  
 Gln Phe Glu Ile Lys Gly Gly Leu Phe Ala Asp Ile Ala Ser His Pro  
 275 280 285  
 Trp Gln Ala Ala Ile Phe Ala Lys His Arg Arg Ser Pro Gly Glu Arg  
 290 295 300  
 Phe Leu Cys Gly Gly Ile Leu Ile Ser Ser Cys Trp Ile Leu Ser Ala  
 305 310 315 320  
 Ala His Cys Phe Gln Glu Arg Phe Pro Pro His His Leu Thr Val Ile  
 325 330 335  
 Leu Gly Arg Thr Tyr Arg Val Val Pro Gly Glu Glu Glu Gln Lys Phe  
 340 345 350  
 Glu Val Glu Lys Tyr Ile Val His Lys Glu Phe Asp Asp Thr Tyr  
 355 360 365  
 Asp Asn Asp Ile Ala Leu Leu Gln Leu Lys Ser Asp Ser Ser Arg Cys  
 370 375 380  
 Ala Gln Glu Ser Ser Val Val Arg Thr Val Cys Leu Pro Pro Ala Asp  
 385 390 395 400  
 Leu Gln Leu Pro Asp Trp Thr Glu Cys Glu Leu Ser Gly Tyr Gly Lys  
 405 410 415  
 Glu Glu Ala Leu Ser Pro Phe Tyr Ser Glu Arg Leu Lys Glu Ala His  
 420 425 430  
 Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn  
 435 440 445  
 Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly  
 450 455 460  
 Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly  
 465 470 475 480  
 Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile  
 485 490 495  
 Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr  
 500 505 510  
 Lys Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro  
 515 520 525

<210> 3  
 <211> 527

<212> PRT  
<213> Homo sapiens

<400> 3

*Bl*  
*Cont*

Ser	Tyr	Gln	Val	Ile	Cys	Arg	Asp	Glu	Lys	Thr	Gln	Met	Ile	Tyr	Gln
1				5					10					15	
Gln	His	Gln	Ser	Trp	Leu	Arg	Pro	Val	Leu	Arg	Ser	Asn	Arg	Val	Glu
		20						25				30			
Tyr	Cys	Trp	Cys	Asn	Ser	Gly	Arg	Ala	Gln	Cys	His	Ser	Val	Pro	Val
	35					40					45				
Lys	Ser	Cys	Ser	Glu	Pro	Arg	Cys	Phe	Asn	Gly	Gly	Thr	Cys	Gln	Gln
	50					55					60				
Ala	Leu	Tyr	Phe	Ser	Asp	Phe	Val	Cys	Gln	Cys	Pro	Glu	Gly	Phe	Ala
65					70					75					80
Gly	Lys	Cys	Cys	Glu	Ile	Asp	Thr	Arg	Ala	Thr	Cys	Tyr	Glu	Asp	Gln
				85					90					95	
Gly	Ile	Ser	Tyr	Arg	Gly	Thr	Trp	Ser	Thr	Ala	Glu	Ser	Gly	Ala	Glu
		100						105					110		
Cys	Thr	Asn	Trp	Asn	Ser	Ser	Ala	Leu	Ala	Gln	Lys	Pro	Tyr	Ser	Gly
		115					120					125			
Arg	Arg	Pro	Asp	Ala	Ile	Arg	Leu	Gly	Leu	Gly	Asn	His	Asn	Tyr	Cys
	130					135					140				
Arg	Asn	Pro	Asp	Arg	Asp	Ser	Lys	Pro	Trp	Cys	Tyr	Val	Phe	Lys	Ala
145					150					155					160
Gly	Lys	Tyr	Ser	Ser	Glu	Phe	Cys	Ser	Thr	Pro	Ala	Cys	Ser	Glu	Gly
			165					170						175	
Asn	Ser	Asp	Cys	Tyr	Phe	Gly	Asn	Gly	Ser	Ala	Tyr	Arg	Gly	Thr	His
		180					185						190		
Ser	Leu	Thr	Glu	Ser	Gly	Ala	Ser	Cys	Leu	Pro	Trp	Asn	Ser	Met	Ile
	195						200					205			
Leu	Ile	Gly	Lys	Val	Tyr	Thr	Ala	Gln	Asn	Pro	Ser	Ala	Gln	Ala	Leu
	210					215					220				
Gly	Leu	Gly	Lys	His	Asn	Tyr	Cys	Arg	Asn	Pro	Asp	Gly	Asp	Ala	Lys
225					230					235					240
Pro	Trp	Cys	His	Val	Leu	Lys	Asn	Arg	Arg	Leu	Thr	Trp	Glu	Tyr	Cys
			245						250					255	
Asp	Val	Pro	Ser	Cys	Ser	Thr	Cys	Gly	Leu	Arg	Gln	Tyr	Ser	Gln	Pro
		260						265					270		
Gln	Phe	Glu	Ile	Lys	Gly	Gly	Leu	Phe	Ala	Asp	Ile	Ala	Ser	His	Pro
	275						280					285			
Trp	Gln	Ala	Ala	Ile	Phe	Ala	Lys	His	Arg	Arg	Ser	Pro	Gly	Glu	Arg
	290					295					300				
Phe	Leu	Cys	Gly	Gly	Ile	Leu	Ile	Ser	Ser	Cys	Trp	Ile	Leu	Ser	Ala
305					310					315					320
Ala	His	Cys	Phe	Gln	Glu	Arg	Phe	Pro	Pro	His	His	Leu	Thr	Val	Ile
			325						330					335	
Leu	Gly	Arg	Thr	Tyr	Arg	Val	Val	Pro	Gly	Glu	Glu	Glu	Gln	Lys	Phe
		340						345					350		
Glu	Val	Glu	Lys	Tyr	Ile	Val	His	Lys	Glu	Phe	Asp	Asp	Asp	Thr	Tyr
	355						360					365			
Asp	Asn	Asp	Ile	Ala	Leu	Leu	Gln	Leu	Lys	Ser	Asp	Ser	Ser	Arg	Cys
	370					375					380				
Ala	Gln	Glu	Ser	Ser	Val	Val	Arg	Thr	Val	Cys	Leu	Pro	Pro	Ala	Asp
385					390					395					400
Leu	Gln	Leu	Pro	Asp	Trp	Thr	Glu	Cys	Glu	Leu	Ser	Gly	Tyr	Gly	Lys
			405						410					415	
His	Glu	Ala	Leu	Ser	Pro	Phe	Tyr	Ser	Glu	Arg	Leu	Tyr	Glu	Ala	His

420 425 430  
 Val Arg Leu Tyr Pro Ser Ser Arg Cys Thr Ser Gln His Leu Leu Asn  
 435 440 445  
 Arg Thr Val Thr Asp Asn Met Leu Cys Ala Gly Asp Thr Arg Ser Gly  
 450 455 460  
 Gly Pro Gln Ala Asn Leu His Asp Ala Cys Gln Gly Asp Ser Gly Gly  
 465 470 475 480  
 Pro Leu Val Cys Leu Asn Asp Gly Arg Met Thr Leu Val Gly Ile Ile  
 485 490 495  
 Ser Trp Gly Leu Gly Cys Gly Gln Lys Asp Val Pro Gly Val Tyr Thr  
 500 505 510  
 Lys. Val Thr Asn Tyr Leu Asp Trp Ile Arg Asp Asn Met Arg Pro  
 515 520 525

<210> 4  
 <211> 290  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
 ctacggcaag catgaggcct tgtctccttt ctattcggag cggctgaagg aggctcatgt 60  
 cagactgtac ccatccagcc gctgcacatc acaacattta cttaacagaa cagtcaccga 120  
 caacatgctg tgtgctggag aactcggag cggcggggccc caggcaaact tgcacgacgc 180  
 ctgccagggc gattcgggag gccccctggt gtgtctgaac gatggccgca tgactttggt 240  
 gggcatcatc agctggggcc tgggctgtgg acagaaggat gtcccgggtg 290

<210> 5  
 <211> 290  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 ctacggcaag gacgaggcct tgtctccttt ctattcggag cggctgaagg aggctcatgt 60  
 cagactgtac ccatccagcc gctgcacatc acaacattta cttaacagaa cagtcaccga 120  
 caacatgctg tgtgctggag aactcggag cggcggggccc caggcaaact tgcacgacgc 180  
 ctgccagggc gattcgggag gccccctggt gtgtctgaac gatggccgca tgactttggt 240  
 gggcatcatc agctggggcc tgggctgtgg acagaaggat gtcccgggtg 290

<210> 6  
 <211> 290  
 <212> DNA  
 <213> Homo sapiens

<400> 6  
 ctacggcaag gaggaggcct tgtctccttt ctattcggag cggctgaagg aggctcatgt 60  
 cagactgtac ccatccagcc gctgcacatc acaacattta cttaacagaa cagtcaccga 120  
 caacatgctg tgtgctggag aactcggag cggcggggccc caggcaaact tgcacgacgc 180  
 ctgccagggc gattcgggag gccccctggt gtgtctgaac gatggccgca tgactttggt 240  
 gggcatcatc agctggggcc tgggctgtgg acagaaggat gtcccgggtg 290

<210> 7  
 <211> 290  
 <212> DNA  
 <213> Homo sapiens

<400> 7

ctacggcaag catgaggcct tgtctccttt ctattcggag cggctgtatg aggtcatgt 60  
 cagactgtac ccatccagcc gctgcacatc acaacattta cttaacagaa cagtcaccga 120  
 caacatgctg tgtgctggag aactcggag cggcgggccc caggcaaact tgcacgacgc 180  
 ctgccagggc gattcgggag gccccctggt gtgtctgaac gatggccgca tgactttggt 240  
 gggcatcatc agctggggcc tgggctgtgg acagaaggat gtcccgggtg 290

<210> 8  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens

<400> 8  
 ctacggcaag gacgaggcct tgt 23

<210> 9  
 <211> 23  
 <212> DNA  
 <213> Homo sapiens

<400> 9  
 ctacggcaag gaggaggcct tgt 23

<210> 10  
 <211> 26  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 cggagcggct gtatgaggct mcatgt 26



MAY 10 2002

Application No. 09/600,985

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216 or (703) 308-2923
- For CRF Submission Help, call (703) 308-4212
- For PatentIn software Program Support:
  - HELP DESK: (703) 739-8559, ext 508, M-F, 8 AM to 5 PM EST except holidays
  - Email: [PATIN21HELP@uspto.gov](mailto:PATIN21HELP@uspto.gov)
  - To purchase PatentIn software: (703) 306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**

COPY OF PAPERS  
ORIGINALLY FILED

**RECEIVED**

MAY 16 2002

TECH CENTER 1600/2900

b